Biotechnology

Fibrobiologics

Fibrobiologics released FY2025 9 Months Earnings on October 31 (EST) with actual revenue of USD 0 and EPS of USD -0.3901

Fibrobiologics released FY2025 Q3 earnings on October 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1341 (forecast USD -0.1075)

Fibrobiologics released FY2025 Q2 earnings on July 31 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1205 (forecast USD -0.1125)

Fibrobiologics released FY2025 Semi-Annual earnings on July 31 (EST) with actual revenue of USD 0 and EPS of USD -0.2555

FibroBiologics Obtains Approval for I Phase Clinical Trials of Cell Therapy for Degenerative Disc Disease

FibroBiologics Inc. to Hold Investor Online Webinar

FibroBiologics Inc. Completes $5 Million Funding

FibroBiologics Annual Shareholders Meeting Elects New Directors and Approves Capital Increase

FibroBiologics Presents Fibroblast Research at SID Annual Meeting

Fibrobiologics released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1354 (forecast USD -0.11)

FibroBiologics Inc. reports Q1 2025 net loss narrows to $5 million

FibroBiologics Presents New T-cell Development Technology at ThymUS 2025

Fibrobiologics released FY2024 Q4 earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.0908 USD (forecast -0.09 USD)

Fibrobiologics released FY2024 annual earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.3394 USD (forecast -0.34 USD)

Fibrobiologics released FY2024 9 Months Earnings on November 12, 2024 (EST) with actual revenue of 0 and EPS of -0.2592

Fibrobiologics released FY2024 Q3 earnings on November 12 (EST), actual revenue 0 USD, actual EPS -0.0149 USD (forecast EPS -0.0866 USD)

FibroBiologics Company Files Patent for Fibroblast Technology in Wound Healing, CEO Highlights Potential

Biotechnology company FibroBiologics submits quarterly report

Fibrobiologics released 3rd Q 2023 earnings on November 28, 2023 (EST), with revenue 0 and EPS -0.3308

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap